Diagnostic role of serum brain-derived neurotrophic factor in HCV cirrhotic patients with minimal hepatic encephalopathy with and without schistosomiasis

Bedewy, Essam S.; Elhadidi, Abeer; El-Latif, Naglaa Abd; Zawawy, Yousra T. El; Abbasy, Amany N.

doi:10.1186/s43066-024-00315-w

Egyptian Liver Journal

Table 1 Comparison between the different studied groups according to different parameters

From: Diagnostic role of serum brain-derived neurotrophic factor in HCV cirrhotic patients with minimal hepatic encephalopathy with and without schistosomiasis

	Group 1 (n = 20)	Group 2 (n = 20)	Group 3 (n = 20)	Group 4 (n = 20)	Test of sig	p
Gender
Male	13 (65%)	10 (50%)	14 (70%)	13 (65%)	χ² = 1.920	0.589
Female	7 (35%)	10 (50%)	6 (30%)	7 (35%)	χ² = 1.920	0.589
Age (years)
Min. – Max	47.0–69.0	42.0–70.0	54.0–68.0	44.0–65.0	F = 2.058	0.113
Mean ± SD	57.20 ± 7.03	59.80 ± 7.72	58.40 ± 3.27	55.10 ± 5.87	F = 2.058	0.113
ALT (U/L)
Min. – Max	24.0–120.0	19.0–120.0	26.0–150.0	13.0–27.0	H = 43.953^*	< 0.001^*
Median (IQR)	40.0(35.50–68.50)	36.50(26.0–44.0)	43.50(36.0–74.0)	18.0 (16.0 – 22.0)	H = 43.953^*	< 0.001^*
p₀	< 0.001^*	< 0.001^*	< 0.001^*
Sig. bet. grps	p₁ = 0.183, p₂ = 0.902, p₃ = 0.146
AST (U/L)
Min. – Max	49.0–151.0	31.0–167.0	38.0–211.0	11.0–38.0	H = 46.696^*	< 0.001^*
Median (IQR)	98.5(60.5–111.5)	57.5(47.50–81.50)	75.5(59.0–117.50)	22.0 (20.50–31.0)	H = 46.696^*	< 0.001^*
p₀	< 0.001^*	< 0.001^*	< 0.001^*
Sig. bet. grps	p₁ = 0.106, p₂ = 0.812, p₃ = 0.168
Albumin (g/dl)
Min. – Max	1.90–3.20	2.20–3.40	2.10–3.60	3.40–4.80	F = 68.614^*	< 0.001^*
Mean ± SD	2.53 ± 0.36	2.95 ± 0.30	2.83 ± 0.35	4.01 ± 0.38	F = 68.614^*	< 0.001^*
p₀	< 0.001^*	< 0.001^*	< 0.001^*
Sig. bet. grps	p₁ = 0.001^, p₂ = 0.035^, p₃ = 0.698
Total bilirubin (mg/dl)
Min. – Max	1.70–6.20	1.0–3.60	0.90–5.70	0.40–1.0	H = 55.513^*	< 0.001^*
Median (IQR)	3.25 (2.20–4.80)	1.45 (1.30–1.95)	2.0 (1.65–2.55)	0.70 (0.50–0.80)	H = 55.513^*	< 0.001^*
p₀	< 0.001^*	< 0.001^*	< 0.001^*
Sig. bet. grps	p₁ = 0.001^, p₂ = 0.048^, p₃ = 0.160
PT (seconds)
Min. – Max	14.80–22.40	13.20–21.80	14.20–19.70	11.50–13.0	F = 32.941^*	< 0.001^*
Mean ± SD	18.44 ± 2.23	16.33 ± 2.80	16.47 ± 1.85	12.25 ± 0.46	F = 32.941^*	< 0.001^*
p₀	< 0.001^*	< 0.001^*	< 0.001^*
Sig. bet. grps	p₁ = 0.008^, p₂ = 0.015^, p₃ = 0.997
INR
Min. – Max	1.30–2.20	1.10–2.10	1.20–1.80	0.90–1.10	F = 30.103^*	< 0.001^*
Mean ± SD	1.69 ± 0.26	1.47 ± 0.31	1.46 ± 0.20	1.03 ± 0.06	F = 30.103^*	< 0.001^*
p₀	< 0.001^*	< 0.001^*	< 0.001^*
Sig. bet. grps	p₁ = 0.012^, p₂ = 0.008^, p₃ = 0.999
Psychometric tests
Average	0 (0%)	12 (60%)	7 (35%)	20 (100%)	χ² = 42.577^*	< 0.001^*
Deficient	20 (100%)	8 (40%)	13 (65%)	0 (0%)	χ² = 42.577^*	< 0.001^*
p₀	< 0.001^*	^FEp = 0.003^*	< 0.001^*
Sig. bet. grps	p₁ < 0.001^,^FEp₂ = 0.008^, p₃ = 0.113

ALT Alanine aminotransferase, AST Aspartate aminotransferase, PT Prothrombin time, INR International normalized ratio, IQR Interquartile range, SD Standard deviation, χ², chi-square test, H Kruskal–Wallis test, pairwise comparison bet. each 2 groups was done using post hoc test (Dunn’s for multiple comparisons test); F, one-way ANOVA test, pairwise comparison bet. each 2 groups was done using post hoc test (Tukey); p, p value for comparing between the different studied groups; p₀, p value for comparing between group 4 and each other group; p₁, p value for comparing between group 1 and group 2; p₂, p value for comparing between group 1 and group 3; p₃, p value for comparing between group 2 and group 3. *Statistically significant at p ≤ 0.05

Back to article page